Final Results of the Subsequent Offer Period of Acorda Therapeutics' Tender Offer for All of the Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp.

ARDSLEY, N.Y.--(BUSINESS WIRE)--The subsequent offer period under the voluntary public tender offer by Acorda Therapeutics, Inc. (Nasdaq:ACOR) ("Acorda" or the "Offeror") to purchase all of the issued and outstanding shares ("Shares"), American Depositary Shares ("ADSs"), stock options, share units and warrants (such securities, collectively, the "Equity Interests") in Biotie Therapies Corp (Nasdaq Helsinki: BTH1V; Nasdaq:BITI) ("Biotie" or the "Company") that are not owned by Biotie or any of its subsidiaries (the "Tender Offer") commenced on 14 April 2016 and expired on 28 April 2016 (the "Subsequent Offer Period").